Xeris Biopharma Holdings (XERS) Other Accumulated Expenses (2020 - 2026)

Xeris Biopharma Holdings' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 2690.38% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 2690.38% YoY) and the FY2025 annual result came in at $4.9 million, up 348.94% from the prior year.
• Other Accumulated Expenses was $4.4 million for Q1 2026 at Xeris Biopharma Holdings, down from $4.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $4.9 million in Q4 2025 and bottomed at $156000.0 in Q1 2025.
• A 5-year average of $1.7 million and a median of $1.1 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses sank 80.52% — and 2026, when it soared 2690.38%.
• Xeris Biopharma Holdings' Other Accumulated Expenses stood at $2.7 million in 2022, then tumbled by 56.09% to $1.2 million in 2023, then retreated by 6.68% to $1.1 million in 2024, then soared by 348.94% to $4.9 million in 2025, then decreased by 10.96% to $4.4 million in 2026.
• Business Quant data shows XERS's Other Accumulated Expenses at $4.4 million in Q1 2026, $4.9 million in Q4 2025, and $2.6 million in Q3 2025.